What's next in general surgery — November 11, 2026
This edition covers what is due in general surgery between mid-November 2026 and February 2027: an obesity meeting opening this week, the comment deadline for an FDA draft guidance on robotic surgery, the FDA filing decision, estimated for January, on a new drug application for a novel analgesic tested in postoperative pain, and the Academic Surgical Congress.
1. ObesityWeek 2026
[Congress] [United States] [Confirmed date: November 14, 2026]
What it is: The Obesity Society's 44th annual meeting, November 14–17, 2026, at the Gaylord National Resort & Convention Center in National Harbor (Maryland, Washington area), with more than 175 scientific sessions; according to the organizers, it spans diet, exercise, lifestyle, and psychology through medical and surgical interventions.
What problem it solves: bariatric surgeons need data to decide when to offer metabolic surgery, when incretin drugs, and how to combine them.
Critical take: data presented only as meeting abstracts are preliminary and best read with caution until full publication.
Sources
- [Meeting] ObesityWeek 2026, The Obesity Society's 44th annual meeting, official page, November 14, 2026. https://obesityweek.org
2. FDA draft guidance on robotically assisted surgical devices
[Guideline in preparation] [United States] [Confirmed date: November 24, 2026]
What it is: the draft guidance "Robotically-Assisted Surgical Devices—Premarket Submissions" (Docket FDA-2026-N-9505, Federal Register, September 25, 2026), with recommendations for non-clinical and clinical testing of teleoperated, software-controlled systems used in open, minimally invasive, or endoluminal procedures. November 24, 2026, is the deadline to ensure that FDA considers comments before it begins work on the final version; according to the notice, comments on any guidance may be submitted at any time.
What problem it solves: it describes what data FDA recommends that a surgical robot manufacturer provide in its US premarket submission, at a time when new platforms are arriving.
Critical take: it targets industry, is non-binding, and may still change. If finalized, it would guide what evidence FDA recommends submitting for certain devices; its effect on surgical practice would be indirect.
Sources
- [Regulator] FDA, Federal Register notice on the draft guidance "Robotically-Assisted Surgical Devices—Premarket Submissions" (doc. 2026-19704, Docket FDA-2026-N-9505), September 25, 2026. https://www.govinfo.gov/content/pkg/FR-2026-09-25/pdf/2026-19704.pdf
- [Regulator] FDA, draft guidance page "Robotically-Assisted Surgical Devices—Premarket Submissions", September 24, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/robotically-assisted-surgical-devices-premarket-submissions
3. Cebranopadol: FDA filing decision estimated for January 2027, based on Adneuris's timeline
[Pending regulatory decision] [United States] [Estimated date: January 2027 (filing decision, about 60 days after submission), per Adneuris Therapeutics]
What it is: a dual nociceptin/orphanin FQ peptide receptor and mu-opioid receptor agonist analgesic. On November 9, 2026, Adneuris Therapeutics, a subsidiary of Tris Pharma, announced it has submitted the NDA to FDA for moderate-to-severe acute pain in adults, based on phase 3 trials ALLEVIATE-1 (NCT06545097, abdominoplasty) and ALLEVIATE-2 (NCT06423703, bunionectomy). Adneuris reported that the 400-µg once-daily regimen reduced cumulative pain scores over the primary assessment window versus placebo in both trials (p < 0.001 for each). The company expects to hear within about 60 days whether FDA accepts the application for filing; only if it is accepted will FDA assign a PDUFA date.
What problem it solves: moderate-to-severe postoperative pain is still managed with opioids carrying abuse and respiratory-depression risk when multimodal analgesia and blocks fall short.
Critical take: sponsor-run trials (Tris Pharma), with the main result reported versus placebo rather than a reference opioid, although ALLEVIATE-2 included an oxycodone arm. The primary window was 4 to 48 h in ALLEVIATE-1 and 2 to 48 h in ALLEVIATE-2, and in ALLEVIATE-1 the regimen of 400 µg on day 1 and 200 µg on day 2 did not reach statistical significance on the primary endpoint. These are selected surgical pain models, and the lower-abuse-potential claim the company makes still has to hold up with FDA.
Sources
- [Official release] Adneuris Therapeutics, November 9, 2026. https://www.globenewswire.com/news-release/2026/11/09/3398339/0/en/adneuris-therapeutics-reaches-key-regulatory-milestone-with-fda-submission-of-new-drug-application-for-cebranopadol-in-moderate-to-severe-acute-pain.html
- [Official release] Tris Pharma, March 6, 2026. https://www.trispharma.com/aapm-2026-painconnect-debut-data/
- [Registry] NCT06545097 (ALLEVIATE-1), ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06545097
- [Registry] NCT06423703 (ALLEVIATE-2), ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06423703
- [Coverage] Consultant360, May 1, 2025. https://www.consultant360.com/conference-coverage/cebranopadol-significantly-reduces-pain-after-abdominoplasty
4. Academic Surgical Congress 2027
[Congress] [United States] [Confirmed date: February 9, 2027]
What it is: the 22nd Academic Surgical Congress, the joint meeting of the Association for Academic Surgery and the Society of University Surgeons, February 9–11, 2027, at the Washington Hilton (Washington, D.C.).
What problem it solves: it is where university groups present outcomes, quality, emergency general surgery, and surgical education studies that later inform local protocols.
Critical take: data presented only as meeting abstracts have not undergone the full review of a published article; it is wise to wait for publication before changing practice.
Sources
- [Meeting] 22nd Annual Academic Surgical Congress (AAS and SUS), official page, February 9, 2027. https://www.academicsurgicalcongress.org
- [Meeting] 22nd Academic Surgical Congress 2027, registration page, February 9, 2027. https://www.academicsurgicalcongress.org/registration/
Ready-to-paste WhatsApp text
*What's next in general surgery — November 11, 2026* 1. ObesityWeek 2026 (metabolic surgery and drugs): November 14–17, 2026. 2. FDA draft guidance on surgical robots: deadline for comments to be considered before the final version, November 24, 2026. 3. Cebranopadol (postoperative pain, NDA submitted): FDA filing decision estimated for January 2027, based on Adneuris's timeline. 4. Academic Surgical Congress: February 9–11, 2027. Full text and audio: https://boletinesmedicos.com/en/general-surgery/2026-11-11-viene.html MedBulletins · boletinesmedicos.com
Ready-to-paste LinkedIn post
What's next in general surgery (November 2026 – February 2027), verifiable dates and official sources only: • ObesityWeek 2026, November 14–17: The Obesity Society's 44th annual meeting, with sessions on medical and surgical interventions for obesity. • FDA draft guidance on robotically assisted surgical devices: November 24 is the deadline for comments to be considered before the final version. If finalized, it would guide what evidence FDA recommends submitting for certain devices. • Cebranopadol, a dual nociceptin/mu-opioid analgesic tested in postoperative pain: NDA announced November 9; FDA filing decision estimated for January 2027, based on Adneuris's timeline. Sponsor-run, placebo-controlled trials. • Academic Surgical Congress, February 9–11, 2027. Full text and audio: https://boletinesmedicos.com/en/general-surgery/2026-11-11-viene.html #GeneralSurgery #RoboticSurgery #PostoperativePain #BariatricSurgery #BoletinesMedicos
Ready-to-paste X (Twitter) post
General surgery, what's next: ObesityWeek (Nov 14–17), FDA comment deadline on surgical robot guidance (Nov 24), cebranopadol for postop pain (filing decision est. Jan 2027), Academic Surgical Congress (Feb 9–11). https://boletinesmedicos.com/en/general-surgery/2026-11-11-viene.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.